Listen to The Lancet: 24 April

Marcia Brose discusses results of a phase III trial of the kinase inhibitor sorafenib for treating radioactive iodine-refractory thyroid cancer.

Source: Listen to The Lancet - April 24, 2014 Category: Journals (General) Authors: The Lancet Source Type: podcasts